Business Wire

Antenna Group Expands Global Footprint with Acquisition of Czech Republic’s Rubikon PR

4.9.2024 13:00:00 EEST | Business Wire | Press release

Share

Antenna Group announced today the acquisition of Rubikon PR, a leading Czech public relations and marketing firm. This move marks a significant expansion of Antenna Group's European operations and reinforces its commitment to driving positive global change through innovative communication strategies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904319818/en/

(Graphic: Business Wire)

Founded in 2012, Rubikon is known for its expertise in social impact, fintech, real estate, technology, and the industrial sector. By seamlessly integrating Rubikon into its global operations, Antenna is both expanding its global footprint and enhancing its ability to deliver creative, data-driven solutions at scale. This strategic integration will provide Rubikon's impressive client roster - including Too Good To Go, Freedom Finance, and SkyShowtime - with access to Antenna Group’s full-stack digital marketing, communications, and public affairs services, as well as its deep domain expertise, and award-winning creative talent.

The synergy created by this union is particularly timely given the Czech Republic's burgeoning climate tech sector. Consumer-friendly regulations in the Czech Republic have made it easier for homeowners to install rooftop solar, and the utility-scale solar industry is in its early stages of development. With a 236% increase in installed PV capacity in 2023, the Central and Eastern European (CEE) region and the European Union present exciting opportunities for sustainable growth and innovation.

"We are thrilled to welcome Rubikon into the Antenna Group family,” said Keith Zakheim, CEO of Antenna Group, “The acquisition is a significant milestone for Antenna as it further strengthens our ability to partner with global companies that are fostering innovation, driving sustainable growth across the planet and making a meaningful impact at scale. This union is not just an expansion of our geographical footprint; but, it amplifies our ability to craft impactful narratives that resonate across borders. This partnership embodies our commitment to fostering a more sustainable future through the power of storytelling, creativity, and technology. Together, we're poised to break new ground, connecting brands with audiences across borders and driving positive change in an increasingly interconnected world."

Šimon Rákosník, EVP of CEE Region, added, "Joining Antenna Group opens up a world of possibilities for our clients and our team. We're excited to combine our local insights with Antenna’s global expertise, particularly in areas like cleantech and sustainable technologies. Together, we're poised to create communication strategies that drive business success and contribute to solving some of the world's most pressing challenges."

This acquisition, following its recent expansion into London, underscores Antenna Group’s dedication to building a truly global, integrated network that can meet clients' evolving needs in an increasingly complex marketplace. By combining Rubikon's regional expertise with its worldwide resources, Antenna is building a powerhouse capable of delivering unparalleled value and driving positive change across North America, Europe, and beyond.

ABOUT ANTENNA GROUP

Antenna Group is a global integrated marketing and communications agency partnering with the world’s most exciting and disruptive companies across climate, energy, mobility, real estate, healthcare, and emerging B2B tech sectors. Our clients are transformational and distinguished corporations, startups, investors, and nonprofits at the bleeding edge of the Age of Adoption — the world today in which companies representing every economic sector are furiously adopting climate tech and sustainable solutions. To learn more, please visit antennagroup.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904319818/en/

Contacts

Media:
Isaac Steinmetz
Antenna Group
isaac.steinmetz@antennagroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release

Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye